Therapeutic Questioning

I wanted to send an email on something I’ve been thinking about sporadically for the past year. That is, “therapeutic questioning”.

I haven’t come across this in any textbooks, but I find that gentle exploratory questions that get a patient to reflect and share their feelings can be helpful. It helps a patient feel seen and understood (by others and themselves).

These can be woven into an interview at opportune moments to encourage reflection, rapport, and resilience.

Here are some examples:

  • Identity:
    • How would you describe yourself to someone who doesn’t know you? 
    • What do you hope people understand about you? 
  • Resilience:
    • What do you often underestimate about yourself? 
    • What moment made you feel proud of yourself? 
    • What has helped you get through today, even a little? 
    • What qualities in you helped you survive before? 
  • Spirituality:
    • What religious or spiritual ideas were you taught growing up? 
  • Challenges:
    • What aspect of things feels heaviest right now? 
  • Comforts:
    • What would make today 1% more bearable? 
    • What do you do differently on days that feel slightly less heavy? 
  • Agency:
    • What helps you feel a sense of control, however limited? 
    • What still matters to you, even if you’re exhausted? 
    • What feels unfinished about your story? 
  • Hope:
    • If things didn’t get better, but got different, what might that look like? 
    • What would a tolerable future look like? 

Additionally: The Miracle Question

Schemide asked a version of the miracle question today, which I like a lot. The miracle question is often part of a form of therapy called “solution-focused therapy”:

Suppose tonight, while you’re asleep, a miracle happens and the problem that brought you here is completely solved. Because you were asleep, you don’t know the miracle happened.
When you wake up tomorrow, what would be the first small sign that lets you know something is different?

Follow up questions that deepen it:

  • What would other people notice about you?
  • What would you be doing instead of what you do now?
  • On a scale from 0–10, where are you today compared to the miracle day?
  • What tells you you’re not at 0 already?

Dysautonomia

The topic of this page is Dysautonomia/POTS, a condition we see occasionally at Shands. This is quite disabling and misunderstood, so I wanted to provide a brief overview.

What is Dysautonomia?

It’s an umbrella term for disorders of the Autonomic Nervous System (ANS).

  • ANS regulates involuntary body functions (HR, BP, digestion, temperature, sweating) 
  • In dysautonomia, ANS responds inappropriately to physiologic demands (standing, eating, stress, heat, exertion) 
  • Includes:
    • POTS (postural orthostatic tachycardia syndrome) – by far, most common 
    • Vasovagal syncope 
    • Multiple system atrophy (neurodegenerative) 
    • Autoimmune autonomic ganglionopathy 
    • Secondary dysautonomia (small fiber neuropathy, DM, Parkinson’s, Ehler’s Danlos) 

What is POTS?

  • Defined by:
    • Excessive HR increase on standing 
    • Without significant drop in BP 
  • Diagnostic criterion:
    • HR increase >30 within 10 min of standing or tilt, without orthostatic hypotension 

How common is dysautonomia? POTS? 

  • Dysautonomia: exact prevalence unknown, likely underdiagnosed 
  • POTS: estimate 0.1-1% of population
    • 80-85% female 
    • Peak onset: adolescence to early adulthood 

What are are the symptoms of dysautonomia? 

  • Cardiovascular
    • Tachycardia, palpitations, presyncope/syncope, chest discomfort, BP lability 
  • Neurologic
    • Paresthesias, numbness, headache, brain fog, blurry vision 
  • Fatigue, sleep disturbance 
  • GI
    • Nausea, early satiety, bloating, abdominal pain, diarrhea 
  • Thermoregulatory
    • Heat/cold intolerance, sweating changes, fever 
  • Respiratory
    • SOB 
  • MSK
    • Pain, weakness, blood poolign in legs/feet 
  • GU
    • Urinary frequency, incomplete bladder emptying, sexual dysfunction 
  • Psychiatric
    • Panic-like episodes, low mood, depersonalization/derealization, irritability 

Why can dysautonomia be confused with psychiatric conditions? 

  • Symptoms overlap with anxiety and panic 
  • Standard labs and imaging often normal 
  • Symptoms worsen with stress 

How do you diagnose it? 

  • Clinical history (most important) 
    • Orthostatic symptoms, triggers: standing, heat, meals, exertion, symptom relief when lying down 
  • Objective
    • Orthostatic vitals 
  • Supportive tests
    • Autonomic reflex testing 
      • Tilt-table testing: objective evidence of orthostatic intolerance 
      • Sudomotor testing: 50% of POTS shows abnormalities 
    • Labs (exclude other causes) 
      • CMP, CBC, thyroid function, EKG 
      • Targeted (based on sx)
        • Morning cortisol 
        • Echocardiography 
        • Supine/standing plasma catecholamines 
        • 24 hour urine sodium 
        • Gastric motility testing 
        • Serum tryptase (mast cell activation disorder) 

What is the treatment? 

  • Non-pharm (first-line) 
    • Increase fluid/salt intake 
    • Compression garments 
    • Physical reconditioning 
    • Avoid heat/prolonged standing 
    • Small, frequent meals 
  • Medications (selected patients)
    • Beta blockers, Ivabradine, fludrocortisone, midodrine, pyridostigmine, SSRI/SNRI (for autonomic modulation, not just anxiety) 
  • Psychiatric support
    • Education/validation, CBT on coping, not sx dismissal 
    • Treat comorbid depression/anxiety 

Avoidant/Restrictive Food Intake Disorder

We often see patients with feeding difficulties that don’t fit with anorexia nervosa, but are more attributable to food aversion/sensory issues. This is known as ARFID or avoidant/restrictive food intake disorder. Here is some background info.

  • Overview:
    • Dx created in 2013 with DSM5. Very recent, so there’s not a lot of data about it.
    • Occurs across the lifespan, including adults
    • More common in males than females
  • DSM criteria:
    • All must be met:
    • Avoidant/restrictive intake due to:
      • Low appetite
      • Sensory aversion
      • Or Conditioned fear/anxiety after aversive eating experiences
    • Results in ≥1:
      • Weight loss or poor growth
      • Nutritional deficiency
      • Dependence on supplements/enteral feeding
      • Psychosocial impairment
    • Not due to:
      • Food unavailability or cultural practice
      • Anorexia or bulimia (no weight/shape distortion)
      • Another medical or psychiatric condition(unless severity is disproportionate and clinically significant)
  • Causes
    • Genetic vulnerabilities
    • Altered brain function/neurotransmitters/circuits
    • Medical illnesses (GI disorders, allergies/intolerances, oral-motor dysfunction, metabolic abnormalities)
    • Anxiety and fear
    • Way to gain control over chaotic circumstances
    • Dysfunctional beliefs about food
    • Early feeding experiences/parenting styles/mealtime routines
    • Family conflict, pressure to eat
    • Cultural norms and societal pressure about “healthy eating”
  • Key distinguishing features
    • Not driven by weight/body image concerns
    • Often first presents in pediatrics/GI clinics, not psychiatry
  • Drivers of food avoidance:
    • Low appetite/lack of interest in food
    • Sensory aversion (taste, texture, smell, temperature, appearance)
    • Fear of aversive consequences of eating
      • GI distress, vomiting, choking
  • Psychiatric comorbidity
    • Anxiety disorders common (GAD)
    • Also:
      • Panic disorder
      • Social anxiety disorder
      • Autism spectrum disorder
      • ADHD
      • Mood disorders
      • Internet gaming disorder
  • Medical complications
    • Similar to anorexia nervosa when underweight
      • Cardiac, endocrine, GI
    • Stunted growth in children
    • Vomiting prominent: electrolyte abnormalities
  • Treatment
    • Psychotherapy
      • CBT, exposure, family-based treatment
    • Medications
      • Appetite stimulants, antidepressants, meds to treat GI symptoms

Benzodiazepine Tapering

One common issue on consult service is patients taking chronic benzodiazepines. A few practical principles are helpful when thinking about tapering.

1️⃣ Short-Term Use 

Patients on a benzodiazepine (except alprazolam) for:

  • < 1 month
  • At manufacturer-recommended doses
    • Example: Lorazepam 2–6 mg/day

Usually do not require a taper.

2️⃣ Longer-Term Use at Standard Doses

Patients on a benzodiazepine (except alprazolam) for:

  • > 1 month
  • At manufacturer-recommended doses

➡️ Can typically be tapered over ~4 weeks as an outpatient. Reduce by 25% q2week, may slow down to 12.5% q2weeks closer to stopping if needed.

If Inpatient, can reduce by up to 10mg diazepam equivalents per day with CIWA monitoring

However:

  • Some patients may require much slower tapers
  • tapering may be months to 1+ year

3️⃣ Very High-Dose 


Approximately ≥ 100 mg diazepam equivalents per day

If taken for several months, these patients are:

  • At highest risk for severe withdrawal
  • At risk for seizures, delirium, autonomic instability

Inpatient management is recommended

Approach:

  1. Convert to a long-acting benzodiazepine (e.g., diazepam)
    1. Rationale:
    2. Smoother taper
    3. Less rebound anxiety
    4. Less severe withdrawal
    5. Lower dropout rates
  2. Taper the long-acting agent by approximately 10% per day inpatient
  3. Monitor closely for withdrawal symptoms and seizures

***Special Note: Alprazolam 

Alprazolam is different because:

  • Short half-life
  • Higher rebound anxiety
  • Less predictable cross-coverage when switching to long-acting agents

If patients do not tolerate conversion to a long-acting benzodiazepine: You may need to switch back to alprazolam and taper directly.

Case Formulation

I want to highlight a skill that can significantly elevate your clinical reasoning and deepen your understanding of patients: formulation.

We all want to understand patients better. How do we deeply get to know patients? Formulation is a great way, and we can document this understanding clearly in our assessments. While we may not always pause to systematically organize these factors, doing so can make our assessments more thoughtful, comprehensive, and clinically useful.

There are several frameworks for formulation. Today, I want to briefly review another practical approach: the 4Ps model.

***This is a practical outline built around factors that we can often readily identify through a good clinical interview. After completing a comprehensive psychiatric evaluation, next time, if time permits, pause and think through these domains. Assembling a list of relevant factors can strengthen the formulation you include in your assessment.

The 4Ps Framework

We consider:

  • Predisposing factors (what makes someone vulnerable)
  • Precipitating factors (what triggered the current episode)
  • Perpetuating factors (what is maintaining the problem)
  • Protective factors (what supports recovery)

Across three domains:

  • Biological
  • Psychological
  • Social

Common Factors to Consider

Biological

  • Predisposing: Family history, TBI
  • Precipitating: Medical illness/injury, substance use escalation, medication non-adherence, pregnancy, sleep deprivation
  • Perpetuating: Chronic illness, ongoing substance use, lack of treatment
  • Protective: Good overall health, absence of substance use

Psychological

  • Predisposing: Attachment style, family structure, rigid/negative cognitive style, low self-esteem
  • Precipitating: Acute stressors
  • Perpetuating:
    • Cognitive: Negative thoughts, cognitive distortions
    • DBT concepts: Emotional dysregulation, poor distress tolerance, help-seeking/help-rejecting patterns
    • Interpersonal: Dysfunctional relationships, role transitions
    • Maladaptive coping strategies
  • Protective: Reflectiveness, ability to mentalize (see others’ perspectives), positive sense of self, adaptive coping, good insight

Social

  • Predisposing: Poverty, limited access to healthcare, discrimination/racism
  • Precipitating: Loss of social support, trauma, financial stress, housing instability
  • Perpetuating: Ongoing lack of support, poor living conditions, financial strain
  • Protective: Strong social supports, religious/spiritual beliefs, financial stability, engagement in healthcare

Takeaway

You don’t need to include every element every time. Even briefly incorporating a few of these factors into your assessment can:

  • Add depth to your clinical reasoning
  • Clarify why the patient is presenting now
  • Help guide more targeted interventions

 I hope this serves as a helpful reminder and framework you can start integrating into your notes.

An aside: 

🔍 Assessing Attachment Style in a Clinical Interview

1. Ask about relationship patterns (not just facts)

  • “What are your close relationships like?”
  • “What happens when you get close to someone?”
  • “How do you handle conflict?”
  • “Do you feel comfortable depending on others?”

2. Briefly explore early relationships

  • “What was it like growing up with caregivers?”
  • “Who did you go to when upset?”
  • “How did they respond?”
    → Look for: consistency vs unpredictability, warmth vs distance, safety vs fear

3. Observe how they relate to you

  • Reassurance-seeking or overly dependent
  • Guarded, distant, minimizing emotion
  • Fluctuating closeness vs withdrawal
  • Fearful of judgment or abandonment

4. Assess coping in distress

  • Seeks support vs avoids others
  • Clingy/overwhelmed vs shuts down
  • Pushes others away but fears being alone

🧩 Quick Heuristics

  • Secure: Comfortable with closeness and support
  • Anxious: Fear of abandonment, reassurance-seeking
  • Avoidant: Avoids closeness, overly self-reliant
  • Disorganized: Mixed/unstable patterns (approach–avoid)

Carbamazepine: Details

Carbamazepine.  

If we find a patient on this medicine at Shands, there are several key factors to be familiar with.

I will also try to find time to later review oxcarbazepine and topiramate.

Dose

Starting dose: 200mg BID

Titration: Increase by 200mg/day until response

Maximum dose: 1600mg total/day

-When tapering off, go slowly to avoid the risk of seizure. (Reduce dose every 2 weeks to 1 month)

    -Can have bipolar relapse

-Monitor the serum level of CBZ as you are titrating to avoid toxicity.

    -Check level every 5-7 days when starting for 3-4 weeks (because level will go down 2/2 autoinduction)

Therapeutic range

  • 4–12 mcg/mL (mg/L)
  • >12 = toxic
  • >25 = severe toxicity

-Prior to starting perform:

    -CBC, liver function, UA, BUN

    -Eye exam

    -HLA-B*15:02 in asians

Different formulations

  • Immediate-release
  • Extended-release capsules
  • Extended-release tablets

-Capsules can be swallowed or opened and sprinkled on food.

Drug Interactions

  • Strong CYP3A4 inducer
  • Can lower levels of many meds
  • When CBZ stopped, drug levels of other meds may increase
  • Check drug interaction checker (ex: uptodate) always when starting or stopping CBZ

Side effects

-Common: dizziness, drowsiness, N/V, pruritus, blurred vision/nystagmus, tinnitus, phonophobia, constipation

-Other: decreased WBC count, rash, photosensitivity, HTN, jaundice (liver injury), fever, urinary retention

-Serious: agranulocytosis/aplastic anemia, SJS/TEN, SIADH/hyponatremia, liver dysfunction

Contraception

  • Reduces estrogen/progesterone levels
  • Decreases birth control effectiveness
  • Recommended birth control: Copper IUD (non-hormonal)

HLA Testing

  • HLA genes may impact the risk of SJS/TEN
  • HLA-B*15:02 allele strongly associated with SJS/TEN
  • Testing recommended in those with Asian ancestry
  • HLA-A*31:01 also a risk, but less severe
  • Other meds
    • Oxcarbazepine risk with these alleles are less
    • These alleles don’t affect risk with lamotrigine
  • These alleles are tested for on genesight test

Dementia-Related Agitation

  • Can be used for aggression/hostility in dementia
  • Evidence base is small though exists
  • Good for assaultive behaviors
  • Use after antipsychotics fail
  • May take 12 weeks or longer for effect
  • Typical dose: 300mg/day, level 5mcg/mL

Akinetic Mutism

We received a consult to evaluate for “abulia vs akinetic mutism”. You may be unfamiliar with these terms. Here is a brief overview:

Definition

Akinetic mutism is the most severe presentation along a spectrum of disorders affecting motivation and initiation.

Least severe      Apathy –> Abulia –> Akinetic mutism             Most severe

These patients have the ability to think, move, and speak. But they lack the drive to initiate.

-Where they land on the spectrum depends on their degree of impairment.

  • Apathy: Low motivation but still functions independently
    • (apathy = nonspecific term and has broader implications than abulia and akinetic mutism which often hint at specific dysfunction in brain circuits as below)

    -Abulia: Marked decrease in initiation, needs prompting to act

    -Akinetic mutism: Near-complete lack of movement (akinesia) and speech (mutism)

        -Initiation is essentially absent, despite prompting

Akinetic mutism is a SYNDROME. When you identify it, you need to investigate its etiology. The term alludes to dysfunction in frontal-subcortical circuits.

Similarly, making a diagnosis of abulia is hinting at dysfunction in frontal-subcortical circuits.

-Usually made in the context of neurologic illness (ie stroke, TBI, neurodegeneration).

Supportive features in diagnosis of akinetic mutism:

-Confirm wakefulness

-Confirm that capacity to move and speak is intact

-Demonstrate lack of spontaneous speech and movement

-Look for stimulant-induced activation (“telephone effect” – they will suddenly answer the phone with a sudden, abrupt stimulus)

-Check affect (minimal distress, different than depression)

-Check history:

    -Hx of frontal lobe lesion, basal ganglia/thalamic stroke, hydrocephalus

    -Imaging supporting frontal-subcortical involvement

Differential Diagnosis/Possible Causes of Low Motivation:

-Neurologic

    -Lesions involving frontal lobe, basal ganglia, thalamus, white matter

-Medication-related

    -Dopamine blockade (antipsychotics), sedatives

-Neurodegenerative

    -Parkinson’s, Alzheimer’s, Frontotemporal dementia

-Psychiatric

    -Depression (however in depression, will want to act, but are unable. In abulia, there is no drive)

-Medical/systemic

    -Delirium, endocrine disorders

Other differentials:

-Catatonia

-Minimally conscious state

-Locked-in syndrome

Pathophysiology:

Failure of frontal-subcortical motivation circuit.

    -Problem at any of the “nodes” within the circuit.

    -Key locations:

        -Anterior cingulate cortex (ACC)

        -Striatum

        -Globus pallidus (GPi)

        -Thalamus

    -This leads to loss of Dopamine-driven “energizing signal” –> over-inhibition of thalamus (via GPi) –> decreased frontal activity –> decreased initiation of behavior and speech

   -Akinetic mutism (AM) = network disconnection syndrome (not a single lesion problem)

Treatment:

    -Treat underlying cause (stroke, tumor, hydrocephalus, etc)

    -Possible meds:

        -Dopamine-based

            -Bromocriptine, levodopa

        -Stimulants/frontal activation

            -Methylphenidate

            -Atomoxetine

        -Zolpidem (diagnostic and therapeutic)

Agitation as Unmet Needs

We get a TON of consults for agitation in delirium and dementia. Our treatment plan often involves prescription of one or more medications. 

But an often underappreciated aspect in care is behavioral interventions

Agitation in a delirious patient or patient with dementia often reflects an unmet need. They do not have the ability to communicate their need, so their behavior is the communication of the need.

Some common needs:

  • Physiologic –***Always start here!***
    • Pain
    • Sleep
    • Hydration
    • Nutrition
    • Elimination (urine, stool)
    • Oxygenation
    • Elimination (urine, stool)
    • Temperature comfort
  • Cognitive
    • Orientation (time, place, situation)
    • Predictability
    • Simplicity
    • Ability to understand what’s happening
  • Sensory
    • Vision (glasses)
    • Hearing
    • Appropriate lighting
    • Reduced noise
  • Emotional
    • Safety
    • Reduced fear/anxiety
  • Social
    • Familiar people/family presence
  • Autonomy –***HUGE!***
    • Ability to make choices
    • Control over body/environment
  • Identity
    • Dignity
    • Sense of self
  • Environmental
    • Reduced overstimulation
    • Day-night cues

When they have agitation, they are trying to solve a problem with a brain that can’t communicate clearly. So your job becomes figuring out:

    -What problem are they trying to solve?

Ex: pulling lines: discomfort, fear

         Yelling: pain, loneliness, or overstimulation

         Refusing care: loss of control

         Trying to leave: need to toilet

Always ask: “What Changed?” to worsen the behavior

Thinking along these lines helps you be more sophisticated in your evaluation of the patient with agitation!

Some other specific scenarios:

***Loss of control:

    -Offer limited, safe choices

        (Instead of you need to stay in bed –> Would you like to walk now or after lunch?)

    -Replace unsafe behavior with safe version

        (Want to get out of bed, have supervised walking)

    -Give them a purpose to work toward

        (Your job is to rest now so you can get stronger to go home)

    -Use presence instead of force

        (Have someone sit with them, engage them)

    -Reduce the prison feeling

        (Open blinds, normalize environment, sit upright)

Agitation due to:

***Discomfort with tubing (ex: NG tubing):

    -Optimize the physical discomfort

        (Check placement, reduce tension, lubricate nares, oral care, ice chips if allowed, treat nausea/pain)

    -Offer choices

        (Do you want to sit up or lie back?)

    -Keep tubing out of direct line of sight

    -Calm the environment

        (reduce noise/clutter, have appropriate lighting)

    -Use sitter to offer presence

        (sit with them, coach them – try taking slow breaths through your mouth)

***Discomfort with restraints:

    -Reassure that they are safe and that restraints are temporary to keep them safe

    -Offer choices

          (Do you want your head up or down? Do you want water now or in a few minutes? Do you want the TV on or off?)

    -Calm the environment

        (reduce noise, appropriate lighting for time of day)

    -Frequent repositioning + Skin care

    -Scheduled release trials

***When a patient can’t communicate (ie: severe TBI):

    -Assume pain/discomfort until proven otherwise

    -Treat “basic needs” first

        (pain, urinary retention, constipation, positioning discomfort, hunger/thirst, temperature, lines/tubes irritation)

    -Look for timing patterns

        (after feeds – GI discomfort, during care – overstimulation or pain)

    -Use trial and response approach

        (test hypotheses, try addressing pain, positioning, toileting – see if agitation improves)

    -Discuss observations from nursing (high yield) or family

    -Calm the environment

***Need to void but not aware catheter meeting that need:

    -Rule out physiologic causes

                                (ensure catheter not kinked, assess for urinary retention or stool burden which can cause urinary urgency, check for UTI/irritation)

    -Offer bedpan or commode trial

          (Sit them upright to mimic normal voiding posture, tell them “we’ll give you a moment” to provide privacy cue)

    -Show them the tubing

        (point to urine bag)

    -Recheck unmet needs (pain, stool, position)

    -Increase supervision

                                (family, sitter)

Depakote Formulations


Recognizing the difference between Depakote formulations can be challenging. We often get asked which one to use. This info should help. We will discuss Tuesday AM.

Learning objectives:

  1. Recommend the best form of depakote for any given situation
  2. Choose a cost-effective depakote option

So, what’s the deal with all these Depakote formulations???

What is the difference between “Valproate” and “Divalproex”?

  • Valproate/valproic acid VS divalproex sodium
    • Valproate/valproic acid = active molecule
      • Valproic acid = acid form
        • Harsher on the stomach
      • Sodium valproate = salt form
      • This is immediate-release form
    • Divalproex sodium
      • Compound made of sodium valproate and valproic acid combined in 1:1 ratio
      • More GI-friendly
    • All forms become valproate in the bloodstream, once absorbed

What is the difference between divalproex DR and ER?

  • Divalproex
    • Formulated as delayed-release and extended-release
    • Less nausea and GI upset
    • Smoother absorption curves
  • Divalproex DR (delayed-release)
    • AKA EC (enteric coated)
    • Has an enteric coating
      • Dissolves in intestine (not stomach)
    • Dosed 2-3x/day
    • Peaks faster than ER
    • Often used inpatient when you want faster effect
  • Divalproex ER (extended-release)
    • Dosed 1x/day
    • Releases slowly over 24 hours
    • Lower peak levels
    • Less sedation and GI side effects
    • 10-20% lower bioavailability than DR
      • If someone on 1000mg DR, they  need 1250mg ER
  • Cost
    • There are generics for both divalproex DR and ER, so cost should be comparable for both
    • Brand name depakote ER is more expensive

What form are the sprinkles, syrup, and IV formulation?

  • Divalproex sprinkles
    • Still divalproex
    • Capsule filled with enteric-coated beads
    • DR not ER
    • Usually BID dosing
  • Valproate syrup (valproic acid solution)
    • Immediate-release liquid
    • Absorbed quickly
    • More GI irritation
    • Good for NG tube, severe dysphagia, need for rapid titration
  • IV valproate (valproate sodium injection)
    • Brand called depacon
    • 1:1 conversion from PO dose
    • Divided q6h
    • Bioavailability 100%
    • Same dose as divalproex DR (DR has a pretty high bioavailability too)

SIAD (aka SIADH)

I’m going to take a stab at explaining a somewhat complex but clinically relevant topic: Hyponatremia. This matters for us because several psychiatric medications can cause SIAD (syndrome of inappropriate antidiuresis).

You may have learned it as SIADH. The preferred term now is SIAD, because not all cases involve elevated measurable ADH levels.

Psychiatric Medications That Can Cause SIAD

Most commonly associated:

  • Oxcarbazepine
  • Carbamazepine
  • Serotonergic antidepressants (SSRI, SNRI, MAOI, TCA)

Less commonly but can also occur:

  • Lamotrigine
  • Valproate/divalproex
  • First- and second-generation antipsychotics

Many non-psychiatric medications and numerous medical conditions can also cause SIAD.

  • Treatment of SIAD can involve fluid restriction and/or re-eval of meds as well as other treatments not discussed here.

How to Evaluate Hyponatremia

The first step is to check serum osmolality.

Serum osmolality reflects how concentrated the blood is

There are three possibilities:

  • Low serum osmolality → Hypotonic hyponatremia
  • Normal serum osmolality → Isotonic (pseudohyponatremia)
  • High serum osmolality → Hypertonic hyponatremia

The type we are concerned about in SIAD is:

👉 Low serum osmolality (hypotonic hyponatremia)

This means there is excess water relative to sodium in the extracellular compartment.

Next Step in Hypotonic Hyponatremia

Once hypotonic hyponatremia is confirmed, the next step is to check:

  • Urine osmolality
  • Urine sodium

Of these, urine osmolality is the key first test.

Urine Osmolality

In SIAD:

  • Urine osmolality is elevated (>100 mOsm/kg)

Key concept:

High urine osmolality = concentrated urine = ADH is active.

ADH (antidiuretic hormone) conserves free water by making the kidney reabsorb water.
When ADH is on, urine becomes concentrated.

In contrast:

Primary polydipsia (the main psychiatric alternative diagnosis) shows:

  • Low urine osmolality (<100 mOsm/kg)
  • Because ADH is suppressed and the kidneys are appropriately dumping excess water.

So:

  • High urine osm → ADH on
  • Low urine osm → ADH off

Urine Sodium

Urine sodium is helpful but less definitive.

In classic SIAD:

  • Urine sodium is typically >40 mEq/L

This happens because SIAD causes mild volume expansion from water retention.
That mild expansion suppresses RAAS, and the kidneys excrete sodium normally or even at higher levels (natriuresis).

Hypovolemia

Another important cause of hypotonic hyponatremia is hypovolemia.

When effective circulating volume is reduced, the body responds by activating:

  • ADH → causing high urine osmolality (concentrated urine)
  • RAAS → causing low urine sodium (the kidneys conserve sodium)

So the classic hypovolemic pattern is:

  • Low serum osmolality
  • High urine osmolality
  • Low urine sodium

Reduced effective circulating volume can occur in two main ways:

  1. True hypovolemia
    • Vomiting
    • Diarrhea
    • Poor intake
    • Diuretics
    • Third spacing (eg, pancreatitis)
  2. Edematous states with reduced effective arterial blood volume
    • Heart failure
    • Cirrhosis

Richa Vijayvargiya, MD

Psychiatry Service Director, UF Shands

Associate Program Director, UF Psychiatry Residency

Assistant Clinical Professor

UF Department of Psychiatry

Consultation-Liaison Division

rvijayvargiya@ufl.edu